Millendo Therapeutics SAS
🇫🇷France
Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome
Phase 2
Terminated
- Conditions
- Prader-Willi SyndromeHyperphagia
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-01-02
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- Millendo Therapeutics SAS
- Target Recruit Count
- 158
- Registration Number
- NCT03790865
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇫🇷Centre Hospitalier Universitaire d'Angers, Angers, France
🇺🇸Winthrop University Hospital, Mineola, New York, United States
© Copyright 2025. All Rights Reserved by MedPath